Omnix Medical Ltd
Omnix Medical is a biopharmaceutical company dedicated to developing and commercializing highly effective antibiotics against resistant pathogenic bacterial strains. Founded in 2015 and headquartered in Jerusalem, Israel, the company focuses on innovative anti-infective drugs inspired by the innate immune system of insects. Their mission is to fight antimicrobial resistance (AMR) and improve global health by providing novel, safe, and effective treatments for life-threatening infections.
Industries
Nr. of Employees
small (1-50)
Omnix Medical Ltd
High-Tech Village Givat Ram Campus, Jerusalem Israel
Patents
Combination of antimicrobial peptides and antibiotic drugs for treating diseases
US-10745452-B2
View Details
Combination of antimicrobial peptides and antibiotic drugs for treating diseases
US-10745452-B2
View DetailsProducts
Clinical-stage antimicrobial peptide for Gram-negative infections (lead program)
A first-in-class engineered antimicrobial peptide developed for intravenous treatment of life-threatening hospital-acquired infections caused by multidrug-resistant Gram-negative pathogens; optimized for potency, stability and rapid bactericidal membrane-disruption activity.
Clinical-stage antimicrobial peptide for Gram-negative infections (lead program)
A first-in-class engineered antimicrobial peptide developed for intravenous treatment of life-threatening hospital-acquired infections caused by multidrug-resistant Gram-negative pathogens; optimized for potency, stability and rapid bactericidal membrane-disruption activity.
Services
Conduct of in vitro assays, animal efficacy and toxicology studies, and preparation of IND-enabling data packages.
Design and execution of Phase I randomized, double-blind, placebo-controlled studies and advancement to Phase II patient trials, including safety, tolerability and PK endpoints.
Conduct of in vitro assays, animal efficacy and toxicology studies, and preparation of IND-enabling data packages.
Design and execution of Phase I randomized, double-blind, placebo-controlled studies and advancement to Phase II patient trials, including safety, tolerability and PK endpoints.
Expertise Areas
- Antimicrobial peptide discovery and optimization
- Preclinical efficacy and safety testing using animal infection models
- Clinical trial management for IV-administered anti-infectives (Phase I/II)
- Bioanalytical pharmacokinetics and LC/MS/MS assay development
Key Technologies
- Engineered antimicrobial peptides (AMPs)
- Cyclic peptide chemistry
- Peptide chemical synthesis
- Peptide lead optimization platforms (natural-source screening)
News & Updates
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
The FDA has granted fast-track designation to OMN6, a novel antimicrobial peptide for treating infections caused by Gram-negative bacteria, including Acinetobacter baumannii. This accelerates clinical development and highlights the importance of OMN6 in addressing antimicrobial resistance.
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
Positive results demonstrated safety, tolerability, and pharmacokinetics of OMN6 in healthy volunteers, supporting further clinical development.
Omnix Medical Receives NIH Grant for the Development of Its Novel Antimicrobial Peptide OMN6
The NIH grant supports the development of OMN6 targeting Acinetobacter baumannii, with preclinical studies showing efficacy and safety.
Omnix Medical Wins €10.8M in EIC Accelerator Funding to Advance OMN6
Funding will support clinical trials of OMN6, a peptide that physically destroys bacterial membranes, preventing resistance.
Omnix Medical Appoints Antonius Schuh to Its Board of Directors
A biotech veteran with over 20 years of leadership experience, Dr. Schuh joins to support the company's growth and development.
Omnix Medical Starts Phase I Clinical Trial of OMN6 in Healthy Volunteers
The trial assesses safety, tolerability, and pharmacokinetics of OMN6, with results expected in Q4 2022.
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
The FDA has granted fast-track designation to OMN6, a novel antimicrobial peptide for treating infections caused by Gram-negative bacteria, including Acinetobacter baumannii. This accelerates clinical development and highlights the importance of OMN6 in addressing antimicrobial resistance.
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6
Positive results demonstrated safety, tolerability, and pharmacokinetics of OMN6 in healthy volunteers, supporting further clinical development.
Omnix Medical Receives NIH Grant for the Development of Its Novel Antimicrobial Peptide OMN6
The NIH grant supports the development of OMN6 targeting Acinetobacter baumannii, with preclinical studies showing efficacy and safety.
Omnix Medical Wins €10.8M in EIC Accelerator Funding to Advance OMN6
Funding will support clinical trials of OMN6, a peptide that physically destroys bacterial membranes, preventing resistance.
Omnix Medical Appoints Antonius Schuh to Its Board of Directors
A biotech veteran with over 20 years of leadership experience, Dr. Schuh joins to support the company's growth and development.
Omnix Medical Starts Phase I Clinical Trial of OMN6 in Healthy Volunteers
The trial assesses safety, tolerability, and pharmacokinetics of OMN6, with results expected in Q4 2022.